Diabetic kidney disease and cardiovascular disease remain the leading causes of morbidity and mortality in people with type 1 diabetes and are exacerbated with longer duration of diabetes and time outside goal glycemic range. Yet, type 1 diabetes is a complex disease with pathophysiology that extends beyond beta-cell injury and insulin deficiency to include insulin resistance and renal vascular resistance, factors that accelerate cardiovascular disease risk. We have shown that metformin improved peripheral insulin sensitivity and vascular stiffness in youth with type 1 diabetes on multiple daily insulin injections or standard insulin pumps. However, metformin's effect on kidney and endothelial outcomes, and the effects of type 1 diabetes technologies, with or without metformin, on any cardiovascular or kidney outcome, remains unknown. Automated insulin delivery systems combine an insulin pump, continuous glucose monitor, and control algorithm to modulate background insulin delivery and decrease peripheral insulin exposure while improving time in target range and reducing hypoglycemia. We hypothesize that automated insulin delivery systems, particularly when combined with metformin, may modulate renal vascular resistance and insulin sensitivity, thereby impacting cardiometabolic function. MANATEE-T1D is a randomized, double-blind, placebo-controlled trial of 4 months of metformin 2,000 mg daily in 40 youth aged 12-25 years with type 1 diabetes on automated insulin delivery systems vs. 20 control youth with type 1 diabetes on multiple daily injections plus a continuous glucose monitor or an insulin pump in manual mode plus a continuous glucose monitor which will assess for changes in calculated renal vascular resistance and gold standard measures of whole-body and adipose insulin sensitivity, arterial stiffness, and endothelial function.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
60
Agent used to modify insulin sensitivity
Diagnostic aid/agent used to measure renal plasma flow and calculate renal vascular resistance
Diagnostic aid/agent used to measure glomerular filtration rate
Identical to Metformin Hcl 1000Mg Tab but without metabolic effects
Children's Hospital Colorado/University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
ACTIVE_NOT_RECRUITINGSeattle Children's Hospital
Seattle, Washington, United States
RECRUITINGRenal vascular resistance
Renal plasma flow will be measured by para-aminohippurate clearance and used to calculate renal vascular resistance
Time frame: 4 months
Glomerular filtration rate
Measured by iohexol clearance
Time frame: 4 months
Arterial stiffness
Measured by SphygmoCor
Time frame: 4 months
Insulin sensitivity
Measured by hyperinsulinemic-euglycemic clamp
Time frame: 4 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.